Given the overlap of AD and T2DM, several anti-diabetic agents have been tested for treatment of AD, with many showing reduced benefits in apoE4 patients, such as intranasal insulin treatment and insulin sensitizer Rosiglitazone trials [53,54]. Here, INS is linked to type 2 diabetes mellitus.